₹2,222.95
+24.20 (+1.10%)
As of 21 Sept 2026, Corona Remedies Ltd share price is ₹2,222.95. The stock opened at ₹2,222.95 and had closed at ₹2,198.75 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹1,336.95 and a high of ₹2,285.00. In terms of performance, Corona Remedies Ltd share price has increased by 25.89% over the past six months and has increased by 52.99% over the last year.
CORONA Stock Price Chart
Corona Remedies Ltd Overview
Market cap₹13,448 Crs
Volume510
Prev. Close₹2,198.75
Year range₹1,336.95 - ₹2,285.00
ISININE02ZQ01018
About CORONA
Corona Remedies is primarily engaged in the business of manufacturing, trading and marketing of Pharmaceutical products.
Corona Remedies Ltd Historical Performance
1 Month Return3.97%
6 Month Return34.85%
3 Year Return-
3 Month Return19.98%
1 Year Return-
5 Year Return-
Corona Remedies Ltd Fundamentals
ROCE(TTM)27.13%
P/E Ratio (TTM)67.74
P/B Ratio18.03
Debt to Equity0.22
ROE24.78%
EPS (TTM)34.62
Dividend Yield0.45%
Book Value121.97
Profit Margin14.32%
Operating Margin18.57%
Corona Remedies Ltd Financials
| Indicator | Mar 26 | Mar 25 |
|---|---|---|
| Revenue | 1,413.83 | 1,202.35 |
| EBITDA | 284.99 | 245.91 |
| Net Profit | 184.85 | 149.05 |
| EPS | 30.22 | 24.37 |
Corona Remedies Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 2,174.43 |
| Resistance 1 (R1) | 2,218.58 |
| Pivot Point | 2,194.27 |
Corona Remedies Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 19-Jun-2026 | 11-May-2026 | 19-Jun-2026 | Final | ₹10.00 |
CORONA Key Leadership Details
Last Updated: Mar 2026
| Name | Position |
|---|---|
| KIRTIKUMAR LAXMIDAS MEHTA | Chairman |
| NIRAVKUMAR KIRTIKUMAR MEHTA | Managing Director & Chief Executive Officer |
| ANKUR KIRTIKUMAR MEHTA | Managing Director |
Corona Remedies Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,876.20+2.12% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,396.50+0.23% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,971.50+2.72% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Corona Remedies Ltd today is ₹2,222.95 on NSE and ₹2,222.95 on BSE.
- The 52-week high of Corona Remedies Ltd is ₹2,285.00, while the 52-week low is ₹1,336.95.
- The current market capitalisation of Corona Remedies Ltd is approximately ₹13,448 crore.
- The P/E (Price-to-Earnings) ratio of Corona Remedies Ltd is 54.97. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Corona Remedies Ltd is 14.28. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Corona Remedies Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for CORONA on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Corona Remedies Ltd has delivered a return of approximately N/A. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Corona Remedies Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 69.00% promoters, -8.87% FIIs, 12.90% DIIs, and 0.89% public shareholders.
Download TradeMobi App
- Real-Time Market Data
- Advanced Trading Tools
- Expert-Backed Research
